Sonogen Medical

Sonogen is commercializing an ultrasonic bone growth stimulation device that optimizes bone fracture healing while providing real-time feedback on patient compliance and the fracture healing process.

In 2018, Sonogen conducted a POC in vivo animal study, in collaboration with Thomas Jefferson University and the Mayo Clinic. In this study, which was recently published in IEEE, our device healed 30% faster than the competition. Our technology has multiple patents pending, and uses a proprietary and ground-breaking fracture healing assessment algorithm that will deliver real-time feedback on device usage and the fracture healing progress.

40% of Americans suffer from poor vascularity, which negatively affects healing. This includes bone fractures; more than 500k people per year with broken bones develop a delayed or non-union fracture. This frequently leads to a surgical endpoint, which is undesirable for all stakeholders (payors, doctors, and patients). Meanwhile, the technology in the bone growth stimulation space is opaque, unreliable, antiquated, and inconvenient to use.

Sonogen has developed an ultrasonic bone fracture healing device that heals 30% faster than current standard of care, and also delivers real-time fracture healing assessment. Our patent-pending technology has been validated in POC testing. Our device is specifically designed to accelerate bone fracture healing, and dramatically improve patient compliance through usage monitoring and real-time healing feedback.

Our sales strategy will leverage a proven pharmaceutical devices sales model, which today account for at least 80% of the sales in the $250 million bone growth stimulation space. Our device will be marketed to orthopedists as the new standard of care for delayed and nonunion fractures. We unlock up to $50M/year in telehealth fees for orthopedists, will save payors up to $12B/year in avoided surgeries, and save patients up to $1B/year in recovered wages.

FounderTrac
UMass M2D2 IMPACT
Innovation Space Science, Inc.